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Clinical Update
Calcific aortic valve stenosis: hard disease in
the heart
A biomolecular approach towards diagnosis and treatment
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Calcific aortic valve stenosis (CAVS) is common in the ageing population and set to become an increasing economic and health burden.
Once present, it inevitably progresses and has a poor prognosis in symptomatic patients. No medical therapies are proven to be effective
in holding or reducing disease progression. Therefore, aortic valve replacement remains the only available treatment option. Improved
knowledge of the mechanisms underlying disease progression has provided us with insights that CAVS is not a passive disease. Rather,
CAVS is regulated by numerous mechanisms with a key role for calcification. Aortic valve calcification (AVC) is actively regulated involving
cellular and humoral factors that may offer targets for diagnosis and intervention. The discovery that the vitamin K-dependent proteins
are involved in the inhibition of AVC has boosted our mechanistic understanding of this process and has opened up novel avenues in dis-
ease exploration. This review discusses processes involved in CAVS progression, with an emphasis on recent insights into calcification,
methods for imaging calcification activity, and potential therapeutic options.
...................................................................................................................................................................................................
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Introduction
Degenerative calcific aortic valve stenosis (CAVS) is the most com-
mon type of valvular disease in the Western world, representing a
substantial and increasing disease burden in the ageing population.1
Upon mild valve obstruction, disease progression with increasing
haemodynamic severity is inevitable. Once symptomatic severe CAVS
has developed, the prognosis without intervention is dismal. Despite
growing knowledge, experience, and technological developments, the
only treatment for (symptomatic) severe CAVS is surgical or trans-
catheter aortic valve replacement (AVR), to which not all patients are
suited.2 Pharmacological interventions have thus far failed to alter the
course of CAVS. Therefore, an unmet clinical need exists to develop
new treatment strategies delaying CAVS progression.
We still lack precise molecular insight in to the pathophysiological
underlying CAVS, although calcification is well known to play a funda-
mental role in progressive valvular narrowing. Today calcification is
no longer considered a passive consequence of ageing but an active
process involving cellular and molecular pathways. The exact proc-
esses underlying the initiation and progression of valvular calcification
remain unresolved.3 Understanding the biomolecular mechanisms
related to the genesis of calcification in CAVS will propel our
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..knowledge and open novel avenues for diagnosis and treatment. In
this review, we summarize the latest research progress in the patho-
physiology of CAVS and offer novel targets holding potential for
pharmacological interventions and imaging.
Aortic valve cusp function
Aortic valve cusps (or leaflets) must be both strong and flexible to
withstand the considerable mechanical stress and strain associated
with valve closure. To maintain cusp function, the specialized cusp
microarchitecture is crucial and consists of three layers: fibrosa, spon-
giosa, and ventricularis4 (Figure 1). Valvular endothelial cells (VECs)
are located at valvular blood-contacting surfaces, constituting a barrier
that regulates valve permeability, the adhesion of inflammatory cells
and paracrine signalling. Valvular interstitial cells (VICs), the major cell
type, are present throughout all valvular layers. Valvular interstitial
cells are key in valve remodelling, regulating both the synthesis and
degradation of extracellular matrix components. Physiologically, VICs
exist in a quiescent state, with similar characteristics to fibroblasts.5
Stimulation of VECs and VICs by molecular and mechanical triggers
including high blood pressure, altered shear stress, cytokines, and
growth factors contributes to CAVS pathophysiology, altering the
local valve environment and making it calcification prone.
Calcific aortic valve stenosis
aetiology
Although the most common cause of aortic stenosis in the Western
world is degenerative CAVS (referred to as ‘CAVS’ in this review),
rheumatic heart disease remains common in developing countries.
Rheumatic aortic stenosis is caused by an abnormal immune
response to Group A streptococcal infections. Calcification is again a
predominant feature, and although this is believed to relate to
chronic inflammation, precise mechanisms remain poorly defined.6
Calcific aortic valve stenosis is accelerated in patients with congeni-
tally bicuspid aortic valves (BAVs) with aortic stenosis developing
several decades earlier than in patients with trileaflet valves. More
than 50% of patients with severe aortic stenosis requiring aortic valve
replacement have BAV.7
Calcific aortic valve stenosis
pathophysiology
Initiation phase
Calcific aortic valve stenosis can be divided in two distinct phases; the
initiation and propagation phase, each dominated by different mecha-
nisms (Figure 2). The initiation phase shows similarities with athero-
sclerosis, both ignited by endothelial activation/damage and an
inflammatory response8 and sharing common risk factors including
age, male gender, body mass index, smoking, hypertension, and ele-
vated lipid levels including Lp(a).9 Moreover, stenotic valves from ani-
mals fed a high-fat diet display similar lesions as found in early human
atherosclerotic plaques.10,11
Classically, the initiation phase is triggered by mechanical stress in
the valve causing endothelial damage and activation. This is perhaps
best illustrated by the accelerated development of aortic stenosis in
patients with BAV that are characterized by altered flow patterns,
increased mechanical stress, and reduced shear stress.12 The endo-
thelial damage results in lipid infiltration and subsequent oxidation,
thereby initiating an inflammatory response within the valvular endo-
thelium involving macrophages, T-lymphocytes, and mast cells.11
Within affected regions, microcalcifications colocalize with lipids.
Formation of microcalcifications is mediated by the release of apop-
totic bodies and extracellular vesicles, in a similar manner to vesicle-
induced calcification in bone and the vasculature.8,13 These
calcification-prone extracellular vesicles function as nucleating sites
for calcium crystal deposition and facilitate formation of hydroxyapa-
tite. Hydroxyapatite crystals in turn set the stage for CAVS progres-
sion by (i) expanding quickly (creating more nucleation sites for
calcium deposition) and (ii) evoking additional pro-inflammatory
responses.5,8,14
Propagation phase: fibrosis and
calcification as hallmarks of disease
progression
Although the initiation phase is mainly mediated by inflammatory
responses, the role of inflammation and lipid deposition is less promi-
nent in the propagation phase (Figure 2). Instead, it is characterized by
fibrosis and accelerated calcification, leading to valvular dysfunction
Figure 1 Aortic valve. Left panel: 3D reconstruction (from bottom to top): aortic valve with three cusps and proximal ascending aorta. Middle
panel: 2D view. Right panel: valvular histology (bottom to top): ventricularis, spongiosa, and fibrosa.
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.and changes in mechanical stress and flow, thereby creating self-
sustaining mechanisms underlying CAVS progression. Pro-fibrotic
processes are mediated by (i) reduced nitric oxide expression follow-
ing endothelial injury15 and (ii) up-regulation of the renin–angiotensin
system (RAS), and formation of angiotensin II (ANGII). Down-regula-
tion of expression of the ANGII type 2 receptor has been shown to
result in a predominant pro-fibrotic profile, resulting in collagen dep-
osition and the facilitation of progressive calcification.16 Calcific aortic
valve stenosis is viewed as a fibrocalcific disease; however, once
calcification becomes abundant, pro-osteogenic mechanisms become
overwhelming, ultimately leading to severe calcification and valvular
dysfunction. The phenotypic switching of VICs into an osteoblast-like
phenotype is thought to be the fundamental step in accelerating valv-
ular calcification, initiated at least in part by inflammation. In the prop-
agation phase, disease progression is driven by calcific regulatory
pathways including Notch, receptor activator of nuclear factor kappa
B(RANK)/receptor activator of nuclear factor kappa B ligand
(RANKL)/osteoprotegerin (OPG), Wnt/b-catenin, and bone
Figure 2 Pathophysiology and potential treatment targets (schematic overview). Upper panel: Progressive calcific aortic valve stenosis stages from
non-stenotic to severe stenosis (left–right). Progressive thickening and calcification result in valvular dysfunction, characterized by decreased cusp
mobility and opening, altered haemodynamics and stress. Middle panel: Cellular involvement in calcific aortic valve stenosis. Endothelial damage trig-
gers lipid infiltration and upon oxidation an inflammatory response involving macrophages, T-lymphocytes, and mast cells. Inflammation triggers phe-
notypic switching of valvular interstitial cells resulting in increased extracellular vesicle release, providing a nidus for calcification. Microcalcification
provokes an inflammatory response, resulting in increased apoptosis and/or delayed phagocytosis thereby expanding calcium deposition. Upon prop-
agation, pro-fibrotic and pro-calcific processes dominate. Pro-fibrotic changes leading to collagen deposition and facilitating progressive calcification
are mediated by reduced nitric oxide expression and up-regulation of renin–angiotensin system. Calcification is the dominant process driving disease
progression. valvular interstitial cell phenotype switching to an osteoblast phenotype is thought to play a role in the progression phase by multiple
regulatory pathways including Notch, receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand/osteoprote-
gerin, Wnt/b-catenin, and bone morphogenetic protein-2. Lower panel: Potential pharmacological interventions.
Calcific aortic valve stenosis 3
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morphogenetic proteins (BMPs).16 Notch-1 is essential in the devel-
opment of the aortic valve during embryology and a mutation in
Notch-1 is associated with development of BAV (but multiple genetic
factors associated with BAV and CAVS have been described17). Also,
Notch-1 is associated with early valve calcification by stimulating
BMP-2.18 Bone morphogenetic protein-2 is up-regulated through
binding of RANKL to RANK. Activation of the RANK/RANKL path-
way results in the formation of proteins involved in calcification such
as alkaline phosphatase and osteocalcin16 and is involved in CAVS
(Figure 2).
Belonging to the multifunctional TGF-b superfamily, BMP-2 is an
important osteogenic differentiation factor. Bone morphogenetic
protein-2 is a key protein in phenotypic switching of VICs and hence
in the development of aortic valve calcification/calcium (AVC).16
Physiologically, BMP is inhibited by matrix Gla-protein (MGP).19 The
vital role of MGP to inhibit vascular calcification was demonstrated in
MGP-deficient mice, showing lethal rupture of severely calcified
arteries >2 months after birth.20 Although the inhibitory function of
MGP on BMP-2 and subsequent VIC differentiation in CAVS seems
evident, MGP also exerts its effect via a second mechanism. Matrix
Gla-protein interacts directly with hydroxyapatite, inhibiting the
growth of hydroxyapatite crystals in vascular tissue.19 Since we
hypothesize that hydroxyapatite crystals are involved in the early
phase of CAVS, MGP is a potential target to inhibit microcalcification.
Matrix Gla-protein is a vitamin K-dependent protein and is present in
two distinct forms: uncarboxylated inactive (ucMGP) and carboxy-
lated active (cMGP). Like all vitamin K-dependent proteins, MGP
requires vitamin K-induced carboxylation to exert its function19
(Figure 3). Vitamin K antagonist (VKA) inhibits recycling of vitamin K,
thereby inducing inactive vitamin K-dependent proteins. Although
VKA is important for prophylaxis of thrombo-embolic events in cer-
tain patient populations, calcification should be acknowledged as a
side effect. In animal models, warfarin treatment increased vascular
and valvular calcification, similar to the MGP knock-out mouse.21 The
detrimental effect of warfarin was also identified in humans, where
patients using VKA demonstrated more vascular and valvular calcifi-
cation.22,23 With our expanding knowledge of CAVS pathophysiol-
ogy, possible treatment targets for pharmacological interventions
become evident.
Pharmacological treatment targets in
calcific aortic valve stenosis
Current guidelines do not recommend pharmacological interven-
tions to halt CAVS progression. However, the importance and need
to reduce or even reverse progression of CAVS is evident.
Therefore, multiple observational studies and randomized controlled
trials (RCTs) have attempted to repurpose commonly used pharma-
cological interventions to slow CAVS progression.
Angiotensin-converting enzyme
inhibitors and angiotensin receptor
blockers
Hypertension affects the stenotic aortic valve and increases afterload,
thereby accelerating left ventricular (LV) hypertrophy. Both LV
hypertrophy and high valvuloarterial impedance are associated with
adverse events in patients with CAVS.24,25 Therefore, current guide-
lines recommend treatment of concomitant hypertension.2
Renin–angiotensin system (RAS) is an important player in cardio-
vascular disease, being involved in pathological processes in both the
valve and myocardium in CAVS. Angiotensin-converting enzyme
(ACE) inhibitors and angiotensin receptor blockers (ARBs) are
well-known attenuators of RAS effects. However, observational ret-
rospective studies investigating the ACE inhibitor effects on CAVS
progression provided conflicting results. Treatment with ACE inhibi-
tors was associated with less AVC26 but did not appear to slow hae-
modynamic progression.27 In principle, ARBs might have superior
effects on both valve fibrosis and calcification,28 but prospective
RCTs are lacking. With respect to the LV hypertrophic response, the
RIAS RCT showed a modest but significant reduction of myocardial
hypertrophy in patients with CAVS treated with ramipril.29 Finally,
clinical observational studies have suggested that ACE inhibitors and
ARBs are associated with favourable effects on symptoms (dyspnoea
and exercise tolerance) and improved survival in patients with
CAVS.30 Again RCT data are lacking.
Statins
Statins are widely used for lipid lowering in atherosclerosis and
inflammation, being a specific inhibitor of hydroxymethylglutarylco-
enzyme A-reductase (HMG-CoA-reductase). Although retrospec-
tive studies suggested that statins might also be of benefit in CAVS,
subsequent RCTs demonstrated that statins in fact have no effect
on CAVS progression or clinical outcomes. This conclusion was
Figure 3 Synthesis of active matrix-Gla protein: schematic over-
view of vitamin K metabolism. The vitamin K cycle has a central role
in the posttranslational carboxylation of glutamate (Glu) to c-car-
boxyglutamate (Gla). Reduction of vitamin K to vitamin K hydroxy-
quinone (KH2) in presence of vitamin K epoxide reductase (VKOR)
(2) or DDT-diaphorase (3). Vitamin K hydroxyquinone is oxidized
during c-glutamyl carboxylation by gamma-glutamyl carboxylase
(GGCX) (1) into vitamin K epoxide (KO). Vitamin K epoxide is
reduced to vitamin K by vitamin K epoxide reductase (2).
Carboxylated matrix-Gla protein is active matrix-Gla protein that is
secreted in the extracellular environment and inhibits calcification
via binding to bone morphogenetic protein-2 or direct inhibition of
calcium crystal formation.
4 F.E. Peeters et al.
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confirmed by a subsequent meta-analysis.31 The most plausible
explanation for this failure is that whilst statins might intervene with
inflammation and lipid deposition in the initiation phase, they have lit-
tle effect once the propagation phase has become established when
fibrosis and calcification are the dominant pathological processes.
Lipoprotein(a)
Lipoprotein(a), the preferential plasma carrier of oxidized phospholi-
pids, is an LDL-like particle, containing additional apolipoprotein(a)
and apolipoprotein-B100. A causal relationship between AVC and a
single nucleotide polymorphism in the LPA locus was suggested.32
Although the precise mechanisms of action of Lp(a) require further
elucidation, there is considerable interest in investigating whether
Lp(a) is a modifiable target in CAVS. Statins are ineffective in reducing
Lp(a);33 however, several other therapeutic agents are currently in
different stages of investigation. IONIS-APO(a)Rx and IONIS-
APO(a)-LRx ([Ligand-conjugated] antisense oligonucleotides target-
ing hepatic apolipoprotein(a) mRNA) have been investigated
in Phase 1 and 2 trials, demonstrating an ability to reduce Lp(a)
concentrations.34 Other promising Lp(a) lowering alternatives
are proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
and Niacin.35 The effects of Niacin/PCSK9 on aortic stenosis are cur-
rently being investigated (‘EAVaLL’. Clinicaltrials.gov identifier:
NCT02109614 and ‘PCSK9 inhibitors in the progression of aortic
stenosis’, Clinicaltrials.gov identifier: NCT03051360).
Bisphosphonates and denosumab
The calcification paradox implies that treatments for bone diseases
(f.i. bisphosphonates or denosumab) might have a beneficial effect on
vascular and valvular calcification while maintaining bone health.36
Bisphosphonates inhibit osteoclast-mediated bone resorption,
resulting in decreased bone loss.37 The inhibitory effect of bisphosph-
onates on vascular calcification was demonstrated in animals.38
Retrospectively, a delay in CAVS progression was confirmed,39
whereas a more recent study failed to show a positive effect on hae-
modynamic CAVS progression or survival.40 These data are, how-
ever, confounded by the disease accelerating effects of osteoporosis.
The ongoing SALTIRE 2 (Clinicaltrials.gov identifier: NCT02132026)
RCT will help determine the true impact of bisphosphonates.
Denosumab, a human monoclonal antibody targeting RANKL, has
been investigated in pre-clinical models. Its binding prevents the inter-
action between RANK and RANKL, resulting in inhibition of vascular
calcification in mice.41 It is being investigated as part of SALTIRE 2.
Vitamin K
Vitamin K is a fat-soluble vitamin consisting of two forms, namely
phylloquinone (vitamin K1, VK1) present in green leafy vegetables
and menaquinones (vitamin K2, VK2) present in fermented food.
Long-chain menaquinones (i.e. MK7) are transported more efficiently
to extrahepatic tissues.42 However, dietary intake of vitamin K is not
sufficient to ensure full activation of MGP.19 Vitamin K supplementa-
tion is an attractive option to replenish vascular vitamin K stores to
ensure optimal calcification inhibition. Vitamin K supplementation in
rats showed regression of warfarin-induced vascular calcification.43
The prospective Rotterdam study was the first to report that dietary
intake of VK2 showed an inverse relation with vascular calcification
and mortality.44 Furthermore, low vitamin K status was shown to be
associated with increased ucMGP levels and coronary artery calcifica-
tion.19 Although promising, these studies were limited by the
short-term follow-up, precluding measurable effects on clinical end-
points. Recently, the first in-man RCT demonstrated that vitamin K
supplementation decelerated valvular calcification on computed
tomography (CT) in a small group of patients with CAVS.45
The effectiveness of vitamin K supplementation to reduce or hold
calcification progression is currently subject of investigation in multi-
ple trials (‘iPACK-HD’. Clinicaltrials.gov identifier: NCT01528800,
‘VitaVasK’. ClinicalTrials.gov identifier: NCT01742273, ‘VitaK-CAC
trial’. ClinicalTrials.gov identifier: NCT01002157,‘BASIK2’.
ClinicalTrials.gov identifier: NCT02917525).
Imaging in calcific aortic valve
stenosis: from assessment of
haemodynamics to disease
progression
The development of potential CAVS therapies creates a need for
novel imaging techniques to assess their efficacy in Phase 2 clinical tri-
als. These would select the most promising agents to proceed to
larger and more expensive Phase 3 trials incorporating clinical end-
points. Several of such imaging approaches are discussed below and
are listed in Figure 4.
Echocardiography
Echocardiography is the most commonly used imaging technique to
assess patients with aortic stenosis, providing detailed information on
aortic stenosis severity, LV wall thickness, and function.2 Despite
slow annual rate of CAVS progression and relatively high scan–rescan
variability, echocardiography is the most commonly used method for
assessing aortic stenosis progression.
Another application of echocardiography is quantification of valve
calcification, using a semi quantitative four-point scale. Although
echo-assessed calcification is an independent predictor of events
(death or AVR) and disease progression,46 it is not widely used largely
because of poor reproducibility and repeatability.
Computed tomography
Non-contrast multislice CT provides a more detailed and reproduci-
ble calcification scoring system. Computed tomography aortic valve
calcification/calcium (CT-AVC) scoring enables quantification of
mass, density, and volume of macroscopic valvular calcification,
expressed in Agatston units (AU), similar to the approach developed
for the coronary arteries. Computed tomography aortic valve calcifi-
cation/calcium correlates well with haemodynamic parameters on
echocardiography.47 Interestingly, women require less calcification to
develop severe CAVS than men, resulting in gender-specific CT-AVC
thresholds for severe CAVS (1275AU/2065AU for females/males),
with additional prediction of subsequent disease progression and clin-
ical events.48 Furthermore CT-AVC demonstrates relatively large
annualized changes and specific calcification patterns provide addi-
tional insight for surgical and TAVI planning.49 Computed tomogra-
phy aortic valve calcification/calcium is therefore appealing as an
alternative method to assess disease severity and progression and
Calcific aortic valve stenosis 5
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..was recommended in the recent ESC guidelines for this purpose.2
Although CT-AVC provides excellent quantification of the estab-
lished valve calcific burden, it does not inform about disease activity
or the biological mechanisms underlying CAVS.
Positron emission tomography
In contrast to echocardiography and CT, positron emission tomogra-
phy (PET) is an imaging technique that informs about the activity of
specific biological processes. Inflammation and calcification can
both be targeted using the PET tracers 18F-fluorodeoxyglucose (18 F-
FDG) and 18F-sodium fluoride (18 F-NaF), respectively. 18F-fluoro-
deoxyglucose has been applied to quantify vascular inflammation in
the carotid arteries, correlating with macrophage infiltration.50
Increased valvular 18F-FDG uptake was demonstrated recently
in CAVS and associated with faster subsequent disease progres-
sion.51–53 However, assessment of valvular 18F-FDG activity is fre-
quently obscured by uptake in the adjacent myocardium54 and may
reflect glucose utilization by a range of different cells or stimulating
mechanisms.55 18F-sodium fluoride has been used for many decades
for the detection of bone metastases and primary osteoblastic
tumours.56 In the vasculature, it has been used to image developing
microcalcification in carotid, coronary, and aortic atheroma57,58 and
in CAVS,59 providing complementary information to CT-AVC.
Indeed, a striking mismatch has consistently been observed between
the localization of the macroscopic calcium deposits on CT and the
developing microcalcification identified by 18F-NaF. 18F-sodium
fluoride preferentially adsorbs to the available surface area of active
hydroxyapatite crystal growth in areas of microcalcification, while
uptake is low in regions with established areas of macroscopic calcifi-
cation.60 Histological validation of 18F-NaF uptake in the valve in
CAVS has been provided, demonstrating a close correlation with
proteins involved in active calcification.59
Prospective longitudinal studies have demonstrated that areas of
microcalcification on 18F-NaF PET develop with time into novel areas
of macroscopic calcification. Thus 18F-NaF PET acts as a good predic-
tor of early disease progression in CAVS.52,59 On this basis, 18F-NaF
serves as a marker of calcification activity in CAVS and holds major
potential as a surrogate endpoint to test the efficacy of novel pharma-
cological interventions.
Conclusion and future
perspectives
Calcific aortic valve stenosis represents an increasing health care bur-
den, leading to either adverse events or the requirement for major
heart surgery. The pathophysiological mechanisms involved in CAVS
initiation and progression are being rapidly elucidated and include
inflammation, fibrosis, and calcification. With this advancing knowl-
edge, we have identified novel therapeutic targets like vitamin K and
new imaging techniques such as 18F-NaF PET that can be used to test
the efficacy of novel agents and further inform our pathophysiological
Figure 4 Role of imaging techniques in displaying calcification in stages of disease progression. Molecular imaging using 18F-sodium fluoride enables
to visualize microcalcification and active calcification from beginning stages onwards. Computed tomography displays macrocalcification and anatomi-
cal changes in latter phases. Echocardiography visualizes anatomical changes and haemodynamic changes (2).
6 F.E. Peeters et al.
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.
understanding. Indeed, several potential pharmacological treatments
are under current investigation to achieve the ultimate goal, i.e. the
inhibition of disease progression in CAVS.
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